Pamidronic acid

Drug Profile

Pamidronic acid

Alternative Names: AHPrBP; Amino hydroxypropylidene diphosphonic acid; Aminomux; APD; Aredia; CGP 23339A; CGP 23339AE; Disodium aminohydroxypropylidenediphosphonate; Disodium pamidronate; IG 7913; Pamidronate sodium; Panorin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Gador; Henkel
  • Developer Andromaco; Drogueria Marco-Med; Gador Paraguay; Hanlim Pharmaceutical; Leti; MAC Laboratories; Nippon Kayaku; Novartis; Raices; Seignior Pharma; Sued Farmaceutica
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Malignant hypercalcaemia; Osteitis deformans; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis
  • No development reported Bone cancer; Cancer pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 May 2005 Clinical data from a media release have been added to the adverse events section
  • 09 Mar 2005 Data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top